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ABSTRACT
The goal of CERVIS is to make a substantial, positive impact in the cervical cancer screening
space through the development of a minimally invasive, cost effective solution that enables
women in low-resource settings to test for cervical cancer on a frugal and effective platform. In
the developed world, there are a variety of options that can aid in early detection, including Pap
smears. However, due to the high cost and laboratory requirements that accompany this
procedure, women in low-resource settings rarely have access to this preventative care or
regular screenings for cervical cancer. Using new research about the changes in the vaginal
microbiome, CERVIS aims to create a frugal, visual diagnostic screening tool for early stage
cervical cancer as an alternative to the existing expensive, invasive, and clinic-dependent
methods. Outcomes will be measured by partnering with a Kenyan NGO to collect data from
several clinics.
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CHAPTER 1. INTRODUCTION
1.1 Background
Cervical cancer accounts for 6.6% of all female cancers worldwide. The WHO states that 90%
cervical cancer-related deaths occur in low and middle income countries, most of which could be
prevented by screening and early diagnosis (WHO, 2018). Additionally, the link between Human
Papillomavirus (HPV) and cervical cancer has been thoroughly established. Around one-half of
individuals diagnosed with HPV infections have high-risk infections. HPV 16 and HPV 18, two
of the most common strains of high risk HPV cause 70% of cervical cancers.
Current HPV infection and cervical cancer screening identify DNA and protein biomarkers from
cervical samples using expensive, high tech devices (see 1.2 Review of Field). These factors
limit test feasibility in low-resource areas, creating a need for new screening technologies.
Team CERVIS1, a group of undergraduate students from Santa Clara University departments of
Bioengineering and Public Health, are building on promising research related to changes in the
vaginal flora to meet this need. Emerging research demonstrates the link between vaginal flora
and cervical cancer, which has informed the device design. Specifically, Fusobacteria is
undetectable in swabs taken from a healthy vagina but constitutes approximately 17% of bacteria
in cervical cancer vaginal samples (Audirac-Chalifour et al., 2016). Despite a more robust library
of scientific journal articles linking protein biomarkers to cervical cancer, the possibility of
bacteria as a biomarker was explored as a cheaper and easier method for cervical cancer
screening. Our goal is to use this research to design an early-stage cervical cancer screening test
using microbial cultivation techniques to consistently and accurately detect the presence of
Fusobacteria.

1

Cervical Cancer Early Response Visual Identification System
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1.2 Review of Field & Critiques of Current Technology
The key to preventing and addressing cervical cancer development is preventative medicine and
routine screenings. The HPV vaccination and Pap smear are most common in developed nations
while Visual Inspection with Acetic acid (VIA) is used more often in poorly resourced areas
(Gaffikin, 1999).
Pap smears and colposcopies are the most common cervical cancer screening methods used in
developed nations to accurately detect both precancerous and cancerous cellular processes within
a swab sample of the cervix (Markovic, 1998). Analysis of Pap smears requires a high degree of
technical and clinical knowledge to identify and swab the cervix correctly to interpret sample
results for appropriate diagnosis . Additionally, expensive equipment to analyze the sample and
laboratory access is required for proper and effective analysis. These procedures have a high
number of false positives. Finally, from an individual patient standpoint, Pap smears and
colposcopy are invasive, painful, and costly (Markovic, 1998).
HPV vaccinations, in combination with cancer screenings, are the greatest preventative measure
against cervical cancer (WHO, 2018). FDA approved vaccinations including Gardasil and
Cervarix have been found to be nearly 100% effective at preventing cervical infections of HPV
16/18, the two strains most commonly associated with the development of cervical cancer. The
Center for Disease Control (CDC) recommends that all women through the age of 26 and all men
through the age of 21 start the vaccination series between the ages of 11-15. While the HPV
vaccine provides protection from HPV infection, it does not offer any therapeutic treatment of
the virus or cervical cancer. Additionally, social stigmas prevent many from getting vaccinated.
The vaccine, delivered in a two or three-part series, must be delivered by a health care
professional in a clinical setting, making it difficult for those with limited access to clinics and
hospitals to receive the full dose of the vaccine. Finally, the vaccine is expensive, costing up to
$330 for an complete dosage.
Visual Inspection with Acetic Acid (VIA) of the cervix is an inexpensive screening method in
poorly resourced areas (Gaffikin, 1999). Trained health workers and nurses work in mobile
screening camps in low income areas to perform this screening test. The test is invasive and can
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cause some discomfort similar to the Pap smear method because of the insertion of a
self-retaining vaginal speculum. After insertion, acetic acid is applied to the cervix and watched
for a reaction between the suspected lesion and the acetic acid (Poli, 2015). Similar to the
limitations of the previous devices, VIA also requires a high degree of technical knowledge to
properly administer the screening, must be done in a clinical environment, and is highly invasive.
If the test is not administered properly, bubbles may still form, resulting in false positives.
Nurx HPV Test tests for molecular markers in cervical tumorigenesis, however, this test
remains out of reach financially for clinics in many LMICs. NurX uses nucleic acid based HPV
screening to test for the presence of high risk strains of the virus. While this method is accurate
and highly specific, it relies on expensive pieces of laboratory equipment that require technical
expertise to operate and understand machine output. (Nurx™).
Roche CINtec PLUS Cytology is a qualitative immunohistochemistry (IHC) test using the p16
biomarker, which is a cancer biomarker specifically linked to cervical cancer. The test is
conducted using microscopic assessment of p16INK4a protein in formalin-fixed,
paraffin-embedded (FFPE) cervical punch biopsy tissues. The test confirms cervical
abnormalities based on hematoxylin and eosin (H&E) stained slides. This test is a more specific
alternative to Pap smear, but is invasive, expensive, requires a clinician, and results in high rates
of false positives (CINtec® PLUS Cytology).
The table below summarizes the benefits and limitations of each of the current innovations to
combat cervical cancer that were mentioned previously.
Table 1: Current Technologies in CC/HPV Screening
Device
Pap smear & Colposcopy

Benefits
Accuracy

Limitations
Invasive
Expensive lab equipment
required for testing
Clinical and technical
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expertise required for analysis
Visual Inspection with Acetic
Acid (VIA)

Inexpensive

Invasive

Primary screening technique

Moderate technical expertise

in low resource nations

required
Low sensitivity if
administered incorrectly

Roche CINtec PLUS

Specific for Ki-67 and p16

Cytology

markers of HPV infection

Invasive
Multiple clinic visits
Specific for ≥CIN-2
Technical expertise required

Nurx HPV test

Ease of use
No clinical training required
to administer the test

Tests only for HPV, not
directly for cervical cancer
Expensive lab equipment
required for testing
Technical expertise required
for analysis

The limitations of these current innovations highlight the need for a cost effective medical
screening device that enables women in low resource settings, without access to high-grade
medical care, to accurately test for cervical cancer. The device must be non-invasive, making it
easier to implement on a global scale. Additionally, the results of the screening should be simply
interpreted and analyzed by individuals with little to no technical medical background.
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1.3 Microbiome Screening Potential
The human microbiome contains a vast diversity of microorganisms that play critical roles in
maintaining health. Each individual has a unique microbiome, and the differences in microbial
populations can make people more resistant or susceptible to illness (Huang, 2018). By
understanding the microbial communities that make up a healthy microbiome and the factors that
affect microbial composition, new ways to diagnose, treat, and prevent a variety of human
diseases are being considered.
The vagina is a complex, dynamic microbial niche within the human microbiome that is
influenced by age, sexual activity, and other lifestyle factors (Huang, 2018). In general, during
female maturation, the ratio of aerobic to anaerobic bacteria increases due to changes in vaginal
pH, hormones, and sexual activity. In women of reproductive age (15-49), the average ratio of
aerobic to anaerobic vaginal bacteria is approximately 1:10 (Gorbach et. al). Below is a table
highlighting some of the principle microbiota within a healthy female genital tract.
Table 2. Select Normal Vaginal Flora
Species

O2 preference

Gram

Morphology

stain (+/-)

Catalase

Prevalence

test (+/-)

in vaginal
flora (%)1

Lactobacillus

Aerotolerant

+

Rods

-

60

Short Rods

-

7.2

anaerobe
Gardnerella

Facultative

Gram

vaginalis

anaerobe

variable

Streptococcus

Microaerophile

+

Cocci

-

34

Facultative

+

Rod

+

40

Agalactiae
Diphtheroids

anaerobe
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Notes:
1)

Values reported are mean values for analyzed vaginal swabs. Source: (Hutt et. al, 2001)

Prior understanding of vaginal health focused on cell turnover, mucus production, and local
immune defenses as important players in the maintenance of a normal vagina (Reid, 2018).
Recently, it has become more clear that bacteria within the vagina also play protective roles and
can contribute to a variety of diseases.
1.4 Significance of Project
Cervical cancer is a women’s health issue on a global scale with an estimated 530,000 women
diagnosed each year, according to the World Health Organization (WHO 2018). HPV
vaccinations are one of the strongest available measures against cervical cancer especially when
used in combination with accurate and routine screening methods such as a Pap smear. These
methods, though commonly used in the developing world, are not widely available to women in
poorly resourced areas for barriers previously discussed.
Additionally, HPV is a viral infection with more than 30-40 subtypes (Dixit, 2011). The most
common oncogenic subtypes of HPV, HPV16 and HPV18, produce E6 and E7 oncoproteins.
Currently, DNA and RNA based tests that require the use of polymerase chain reaction (PCR)
are most commonly used to diagnose HPV (Engstrom-MeInyx, 2014). To eliminate the need for
PCR, the proposed device uses a bacterial biomarker to produce a binary output based on the
work of Audirac-Chalifour et al., thus contributing to the field of microbiology (2016).
In 2008, the National Institutes of Health (NIH) launched the human microbiome project to
understand the microbial microenvironments in the human body and how these microbial flora
contribute to human health and disease (Gevers, 2012). The vaginal microbiome was explored to
gain insight into the means by which vaginal microbiomes fight against urogenital diseases.
Using pyrosequencing of barcoded 16s rRNA genes, the researchers identified communities that
were clustered into five groups. Although this project produced a baseline for understanding the
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healthy vaginal microbial community, questions remain as to how to further quantify and define
“healthy.”
Researchers under the guidance of Dr. Ami Bhatt, Stanford University’s Director of Global
Oncology, are looking beyond the results from the human microbiome project to understand
variations in the microbiome resulting from factors including location and lifestyle. Bhatt’s
research aims to draw conclusions on the microbiome that can be broadly applied, focusing on
populations living in areas that are in the process of industrialization gaining access to new,
processed foods to get a holistic look on the microbiome and its relation to health. Once
published, research from this study will influence how CERVIS is used in the field.
The CERVIS project is novel because it contributes to the growing field of microbiology,
looking not at traditional protein biomarkers that require expensive analytical techniques but at a
bacterial biomarker that is upregulated in the presence of precancer and cervical cancer. By
designing a test capable of screening for the presence of Fusobacterium spp., a screening method
for implementation in low- and middle-income countries around the world will improve access
to care and empower women, reducing the burden of disease.
1.5 Proposed Goals, Objectives, and Expected Results
During the Fall of 2018, specific goals, objectives, and expected results were created and agreed
upon by all members of the team. These goals dynamically shifted throughout the year, as
decisions were made about the biomarker of interest and the intended target community. Table A
outlines the initial goals, objectives, and expected results as they were understood during the
early stages of the project.
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Chapter 2: PROJECT OVERVIEW
2.1 Target Population
Cervical cancer ranks as the first most common female cancer in Kenyan women ages 15 to 44
years old with over 5,000 cases diagnosed annually (De Sanjosé et al., 2007). The current target
population for CERVIS pilot testing and implementation is Kenya, due to the high incidence and
mortality rate of cervical cancer. Kenya also has an extremely high incidence rate of high risk
strains, HPV 16/18, as it is more than double that of the United States and other developed
countries. Currently, 68% of Kenyan women diagnosed with cervical cancer will die from the
disease, making cervical cancer the first leading cause of cancer death in women (De Sanjosé et
al., 2007). Many of these deaths could be prevented by HPV screening and early diagnosis of
cervical cancer; however there is a lack of a low cost, non-invasive screening for low resource
settings (Coleman et al., 2016).
2.1.1 Customer Needs & Cultural Relevance
Cervical cancer is the leading cause of cancer deaths in sub-Saharan Africa (WHO, 2018), and
the incidence is likely underreported due to poor cancer registration (Kimani, Sherif, & Bashir,
2012). Cervical cancer screening methods including Pap smear and VIA have significantly
reduced the burden of disease in several sub-Saharan African countries, and the “screen-and
treat” approach allows for women who test positive to receive cryotherapy immediately
following diagnosis (Coleman et al., 2016).
Although these methods are available in Kenya as part of the Ministry of Health’s National
Cervical Cancer Prevention Strategic Plan from 2002-2006, adoption remains low because these
methods are invasive, they have difficulty navigating cultural barriers, and most women do not
seek out medical treatment until they suspect a health issue (WHO, 2018). Additionally, the
negative stigma about cervical cancer and fear of screening results prevent screening methods
from being more widely employed. If screening and treatment for cervical cancer does not
increase, the number of cervical cancer deaths is estimated to double in Kenya by 2025,
demonstrating the need to educate women about cervical cancer screening and treatment options
(Sudenga, 2013). Increasing smartphone usage rates in Kenya provides a technological platform
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that can reduce prevailing barriers and thus the burden of disease (Poushter, 2016). Additionally,
eliminating the need for women to travel to the clinic by focusing efforts on designing
in-the-field screening methods has the potential to address cervical cancer deaths in low and
middle income countries.
2.2 Project Components
A list of device criteria were defined based on the culturing conditions of the selected bacterial
biomarker and the development of a screening device (Figure 1). First, in order to create a binary
output, meaning the test detects the absence or presence of this species of bacteria, the device
must be capable of selectively growing the bacteria of interest from a patient sample. Secondly,
the device must maintain an anaerobic environment during the growth period because
Fusobacterium is unable to grow in the presence of oxygen. And finally, the device must
seamlessly incorporate the patients sample to allow for ease of use and result interpretation.
These criteria were organized depending of the form of the device or the function of the device.
Experiments were designed to address each of these criteria, and the results of these experiments
ultimately informed the design of the proposed screening device.

Selective
Function
Anaerobic
CERVIS
Sampling
Mechanism
Form
Self-Contained
Tube

Figure 1: Subsystems Overview
2.2.1 Bacterial Biomarkers of Interest
Proteins were originally explored as biomarkers indicative of cervical cancer for this project.
DNA amplification arose as an issue when dealing with these biomarkers because DNA
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amplification is done by polymerase chain reaction (PCR) and subsequent analysis by
sequencing or gel electrophoresis. PCR uses a strand of template DNA, the enzyme taq
polymerase, primers, and exposure to repeated cycles of heating and cooling, which is done
using a PCR machine that typically costs between $800 and $20,000. The primers, template
DNA, and enzyme must be preserved by refrigeration.
Because CERVIS is intended for use in low- and middle-income countries, this route proved
ineffective based on the need for expensive laboratory equipment and refrigeration. The link
between vaginal microbiome diversity or concentrations and their association with HPV,
precancerous lesions, and cervical cancer was explored as a promising alternative to protein
biomarkers (Audirac-Chalifour et al., 2016). Additionally, using bacterial biomarkers showed
potential for cheaper and easier culturing methods. Lactobacillus and Fusobacterium were
explored as potential target biomarkers for CERVIS.
2.2.1.1 Lactobacillus
Lactobacillus is often the predominant species in the normal vaginal microbiome
(Audirac-Chalifour et al., 2016). Given the abundance of Lactobacillus in a healthy vaginal
microbiome, Lactobacillus was chosen to test the efficacy of using bacterial biomarkers. Initial
experiments were designed to isolate lactobacillus from the vaginal microbiome. The purpose of
these experiments was to both learn microbiology laboratory techniques and understand the
difficulty in selecting against related species for the isolation of one particular bacteria.
This species plays a critical role in regulating the presence of other vaginal flora as well as
protecting the host from pathogens (Larsen and Monif, 2001). Mechanisms for pathogen and
microbial inhibition have been attributed to the ability of Lactobacillus to produce
hydrogen-peroxide, an oxidizing agent that disrupts the plasma membrane of certain microbes, as
well as lactic acid which can alter the pH within the vagina (Larsen and Monif, 2001). Previous
studies show a significant correlation between absence of hydrogen-peroxide producing
Lactobacilli and colonization by bacteria associated with vaginal disease as well as an increased
abundance of Lactobacilli in in young adolescents (Hiller et. al). Both of these findings point to
the importance of Lactobacillus in defending the host from potential pathogens.
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Previous research has identified Lactobacilli at the genus level by gram stain, colony
morphology, and catalase test (Hütt et. al, 2016). Specifically, Lactobacilli are gram positive, rod
shaped, and produce a negative catalase test (Hütt et. al, 2016).
2.2.1.2 Fusobacteria
Studies show that Fusobacterium spp. is undetectable in vaginal swabs from a healthy vagina but
constitutes approximately 17% of bacteria in a vaginal sample from a cervical cancer patient
(Audirac-Chalifour et al., 2016). Based on this information, this bacteria species was chosen as
the final bacterial biomarker used in CERVIS.
Fusobacterium spp. is an anaerobic, gram-negative bacteria usually absent in healthy tissue but
upregulated in instances of disease. Fusobacterium nucleatum is associated with inflammatory
diseases including appendicitis and ulcerative colitis, as well as multiple cancers, including
colorectal, oropharyngeal, and cervical cancers (Audirac-Chalifour et al., 2016).
Our team selected a strain of F. nucleatum and F. necrophorum to investigate practical
field-based cultivation methods for obligate anaerobes. By conducting a series of experiments, a
set of criteria was developed for the optimum culturing of fusobacterium nucleatum and
necrophorum without an anaerobic hood, which is unavailable in frugal contexts.
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Figure 2: The Link between Fusobacterium and Cervical Cancer (Astride
Audirac-Chalifour, 2016).
2.2.3 Physical Manifestation of the Assay
2.2.3.1 Device Format
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The assay development was an iterative process. As initial laboratory results were collected, the
anaerobic requirement for the future prototype was realized. In creating initial sketches, the
designs took two forms, a plate and tube design (Figure 3). The tube design with semi-solid
media was determined the best option for maintaining an anaerobic environment for
Fusobacterium growth and detection. The tube design with the swab inserted and twist helped
maintain an anaerobic environment capable of growing fusobacteria. To justify the final device
format, questions were answered about the density of the media and the shape of the device for
anaerobic maintenance and optimal growth conditions.

The plate design reduced the possibility of creating a truly anaerobic environment. Creating a
sealed enclosure that made the entire chamber remain anaerobic posed a challenge because a
larger surface area would be exposed to oxygen upon sample introduction. Furthermore, the
application of the plate design required a more in depth understanding of microbiology and of
microbiology techniques to properly streak the plate.
Tube Design

Plate Design

Figure 3: Initial Prototype Ideations
2.2.3.2 Swab Collection
To determine the optimal collection method, five cytology applicators- the Cervex brush, the
cervical spatula, the cotton swab, the polyester swab, and the bristle brush- were chosen to
measure the amount of oxygen introduced into a semi-solid media in a closed glass tube. In

20
addition to oxygen exposure, the swabs were each evaluated based on criteria of size, toxicity,
and sample collection.
2.2.4 Growth Media
To create the media for the growth of Fusobacterium, several conditions were required. The
media had to be nutrient-rich to support the growth of bacteria and had to be selective for the
growth of Fusobacterium. Additionally, the media had to be transparent in order to easily
observe growth. Finally, the media, in combination with the device form, was required to
maintain anaerobic conditions to support the growth of fusobacterium, an obligate anaerobe. To
meet these criteria, several ingredients were included in the media: Brain Heart Infusion broth,
antibiotics, and Gelrite.
The media recipe was tested for functionality and altered to improve results in two different
iterations. The results of each iteration and the criteria for altering the recipe are discussed in 4.2.
2.2.4.1 Anaerobic Conditions
Since Fusobacterium is an obligate anaerobe, the media also needed to be able to maintain
anaerobic conditions within the tube. Currently, it is challenging to keep liquid media tubes free
of oxygen because it is more easily mixed throughout the media even if only the surface becomes
exposed to oxygen (See 2.2.3.2). To achieve a semi-solid consistency, Gelrite was added to the
media. Gelrite was used instead of agar because it allows the same consistency as agar but
prevents cloudiness when the media is poured. Oxygen inevitably enters the tube when it is
opened for sample penetration. While the semisolid media prevents the oxygen from spreading
throughout the media, it does not actively reduce the amount of oxygen in the media. To address
this concern, an oxygen scavenger was incorporated into the CERVIS 1.0 formula. Additionally,
an oxygen indicator was added to the media to identify oxygen exposure. When oxygen enters
the system, the resazurin reacts with the oxygen to turn blue, showing exactly where oxygen has
entered the media. This allowed close monitoring of the anaerobicity of the media.
2.2.6 Educational Component
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An educational component teaching women about their anatomy, the risks of cervical cancer,
and the importance of screening will be developed with the help of local community members
for ensured cultural relevance and incorporated into the device implementation strategy. This
program will extend to both patients and providers to increase screening uptake by the women
living in the community and minimize the risk of false positive results. This is an important step
in navigating cultural barriers and ensuring that the device is implemented in the most effective
and ethical way. This component was outside the scope of the project for this year, but a
preliminary outline of next steps is discussed in Chapter 6.
2.3 Team and Project Management
The project team is composed of four Santa Clara University (SCU) faculty members, four
bioengineering students, and three public health students from the Engineering World Health
(EWH) partnership. The faculty advisors are Dr. Prashanth Asuri, Dr. Michele Parker, Dr. Craig
Stephens, and Dr. Tracy Ruscetti. Dr. Prashanth Asuri has served as a Bioengineering and
Bioinnovation advisor. Dr. Michele Parker has served as a public Health advisor and a mentor to
the Engineering World Health aspect of the project. Dr. Craig Stephens has served as a
Microbiology advisor and mentored the students in common microbiology techniques.
Additionally, Dr. Stephens provided the students with lab space and supplies. Finally, Dr. Tracy
Ruscetti has also served as a Microbiology advisor, training the students in the anaerobic
chamber and assisting with experimental design. The public health students that partnered with
the bioengineering students through EWH are Dave Heil, Nicola Gerbino, and Mason Seeley.
The project originally stemmed from the work of a 2017-2018 senior design group. Within the
bioengineering student group, all experimental design, presentations, team member
communication, company visits, and lab work were completed as a team. In terms of individual
roles, Claire Hultquist managed supplies orders, Julia Lanoha planned School of Engineering
showcasing dates, Rosie McDonagh organized meeting notes, and Hallie McNamara was the
lead contact with EWH.
2.3.1 Budget
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The funds for necessary supplies for experimentation and development of the frugal screening
biodevice were requested from the Santa Clara University Undergraduate Programs. The
awarded funding for the Frugal Cervical Cancer screening is summarized in Table B found in the
appendix. Additionally, a detailed outline of the expenditures of the project totalling $1,230.27
can be found in Table C in the appendix.
2.3.2 Timeline
Reference appendix A for a complete overview of completed action items for the CERVIS
project between Fall 2018 and Summer 2019.

23

CHAPTER 3: Bacteria Biomarkers of Interest (Subsystem A)
3.1 Introduction
Up until the 1970s, there was poor characterization of the vaginal microbiome due to the narrow
range of media and oxygen levels that allow for cultivation of these bacteria (Larsen and Monif,
2001). Today, over 150 different bacterial species have been characterized as populates of the
vagina that participate in many interactions within this ecosystem (Larsen and Monif, 2001).
Being able to rapidly recognize changes in vaginal flora and how this corresponds with specific
disease states has a number of implications for screenings and the future of personalized
medicine. Similar to the way a patient’s blood pressure and weight is monitored over time,
tracking changes in an individual’s vaginal flora at different stages of their lifespan (i.e.
childhood, adolescence, reproductive age, later adulthood) can provide healthcare providers with
a more comprehensive understanding of a patient’s health (Larsen and Monif, 2001).
Experiments which examine the bacteria present in a patient’s vaginal microbiome can be scaled
up and translated to a comprehensive library with bacterial concentrations, species presence, and
associated patient factors that can be used to monitor an individual’s health and how it is related
to the vaginal microbiome.
To reduce the risk of producing false positive results, bacterial biomarkers were considered with
the potential of producing a binary outcome. Relying on reading a bacterial gradient with an
array of microbes present in the vaginal microbiome requires further quantification and analysis
beyond the scope of our device. Lactobacillus and fusobacteria species were selected for further
investigation for possible device integration. Lactobacillus was selected based on its high
prevalence in the healthy vaginal microbiome and involvement in regulating the vaginal pH. The
first steps in this experiment were to determine whether vaginal microbes could be cultivated
from vaginal swabs on rich media as well as the optimal aerobic environment for growth.
Fusobacteria was selected due to its association with different disease states present in the
vagina. Experiments were designed to inform the final device design.
3.2 Methods
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An in depth literature review was conducted, evaluating the current literature on the vaginal
microbiome and the present microbes association with disease state, specifically cervical cancer.
Peer-reviewed articles were selected using the SCU One Search feature on the Santa Clara
University library website. The findings from this review are summarized in the Table E in
Appendix A.
Lactobacillus
Culturing Vaginal Samples
Four female students from the Fall 2018 Santa Clara University microbiology class took three
sterile cotton swabs to procure three vaginal samples. Each vaginal sample was used to inoculate
a separate tryptic soy agar (TSA) plate. The plates were cultivated in the 37°Celsius incubator for
48 hours in different aerobic conditions: aerobic, anaerobic, and microaerophilic. To achieve the
anaerobic growth condition, a “GasPak” culture system was enlisted. In the GasPak jar, the gas
generator envelope uses a catalyst to combine Oxygen gas with Hydrogen gas, which removes
O2 from
the sealed container. To create the microaerophilic system, a candle was placed on top of

the inoculated plates, lit, and then sealed in a jar. The flame from the candle consumes oxygen in
the sealed chamber and produces carbon dioxide until it is finally extinguished due to insufficient
oxygen quantity creating a microaerophilic environment. Oxygen test strips were placed in both
the anaerobic chamber and candle jar system to assess the effectiveness of these chambers in
producing the desired oxygenation levels.
After 48 hours, each plate was examined for growth. Colonies that appeared to be distinct
species based on color and morphology were each analyzed via Gram stain and catalase test. The
procedures enlisted for both of these tests were taken from Dr. Craig Stephens’ Biology 113Microbiology Lab Manual. To perform the Gram stain, a distinct colony from each separate
identified strain was picked using a sterile loop and then smeared on a clean glass, microscope
slide. The colonies were then heat fixed to the slide by passing the slide through the fire three
times. Following this, the smears were flooded with the primary, crystal violet, stain and were
left to sit for a minute. Afterwards, the slides were rinsed with deionized water. After the rinse,
the slides were flooded with the mordant (Gram’s Iodine) and were left to sit for a minute. The
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slides were then rinsed again with deionized water. Decolorizer, ethanol, was applied and then
the slide was left to sit for 15-30 seconds. After another rinse, the slides were flooded with
counterstain, safranin, and left to sit for 30 seconds. Following this final stain, the slides were
rinsed again then blotted. Once the slides dried, the staining pattern of the specific species, the
general cell morphology, and organization were visualized using a light microscope.
Isolating Lactobacillus
Four female microbiology students inoculated selective media with their respective vaginal
swabs. The medias used were blood agar and Man-Rogosa-Sharpe (MRS); both have been
reported to be selective for Lactobacillus (Pendharkar et al. 2013). After 48 hours, any microbes
that needed to be isolated were restreaked. Those that did not require isolation were analyzed
using the same procedures as those listed above. Once the colonies that were re-streaked had
spent 48 hours in the incubator, the analysis procedure were repeated on the resulting isolates.
Next, the isolates were prepared for 16s ribosomal DNA PCR. First, each colony was suspended
in 20 microliters of sterile, deionized water. Then, the remaining PCR components were added to
the mixture. These components include 10 microliters of GoTrg buffer, 1 microliter of dNTP’s,
0.5 microliters of GF primer, 0.5 microliters of 149z R primer, 0.2 microliters of GoTag, and 17
more microliters of deionized water. Once this mix was prepared, the 16s ribosomal DNA
components were amplified via PCR. Following this preparation, these genetic fragments were
run through a gel. Due to ineffective primers, the gel did not produce accurate results, so this
process was repeated. With confirmation that the PCR procedure was successful, the isolates’
genetic information was be sent to a lab for DNA sequencing. The results are summarized in
table 8.
Fusobacterium
F. Nucleatum ATCC 25586 and F. Necrophorum ATCC 255386 were streaked for isolation
using a disposable sterile loop on Anaerobe Systems2 Brucella Blood Agar (BRU) and
Fusobacterium Selective Agar (FSA). These plates were incubated at 37°Celsius under anaerobic

2

Media produced

environment.

by Anaerobe Systems is manufactured and packaged in a deoxygenated
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conditions for 48 hours. Anaerobic conditions were met using an anaerobic chamber, with an
internal environment comprised of 90% N2, 5% CO2, and 5% H2. BRU media was chosen as a
positive control, supporting the growth of Fusobacterium spp. (Brucella Blood Agar- BRU,
2018). FSA is an enriched selective medium for the isolation and presumptive isolation of
Fusobacterium species, chosen to inform the formulation of CERVIS media discussed in
Chapter 5 (Fusobacterium Selective Agar- FSA, 2018).
3.3 Results
Lactobacillus
Culturing Vaginal Samples
Growth was achieved on the TSA plates for 15/16 samples. The observed size and shape of the
colonies varied between the three respiratory conditions. Colonies grown under anaerobic
conditions were the smallest and most abundant making them difficult to differentiate, while
colonies on aerobic plates were dominated by large, circular colonies that we suspected were
yeast given the aerobic growth conditions. After Gram staining the colonies from the TSA plates,
it was found that almost every bacteria from these colonies was Gram positive. Additionally, all
of the cultivated bacteria had a relatively similar morphology: cocci in either chains or clusters
with positive catalase tests.
Isolating Lactobacillus
Limited microbial growth was attained on the MRS plates, and the analysis of colonies from
these plates was inconsistent, so the data from these plates was discarded. Additionally, many of
the colonies that grew on the aerobic plates were identified as yeast and our target bacteria
Lactobacillus is an aerotolerant anaerobe. As a result, the plates grown in the aerobic condition
were also discarded to help increase selectivity for Lactobacillus. Thus, only the data obtained
from the analysis of the microbes on the anaerobic blood agar plates was enlisted to determine
the species each group member cultured.
All members of the group achieved growth on blood agar media under both aerobic and
anaerobic conditions. A majority of plates in the anaerobic condition appeared to have a film of
condensed, small colonies while the colonies on the aerobic plates were larger, and more
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defined. Though there were differences between vaginal samples, in general there was more
limited growth on MRS plates under the varying oxygen levels. Although growth was evident in
both aerobic and anaerobic conditions, we believe that many of the large colonies on our aerobic
plates, for MRS and blood agar, were yeast. Consequently, the aerobic plates were discarded
from the data set and not used for subsequent testing and isolation. The remaining anaerobic
MRS plates were also discarded due to a lack of consistent growth.
PCR was run for seven of the isolated colonies. None of the sequenced colonies derived from
subject’s vaginal samples proved to be in the genus lactobacillus. The results are summarized in
table 8. All identified species are commonly found in the vaginal microbiota, which as you know
is fairly variable between individuals. The Streptococcus isolates are the closest relatives of
Lactobacillus.
Table 3: Summary of Findings from Attempt to Isolate Lactobacillus
Edited
Sample

Primer

Sequence
Length (bp)

13;8F.ab
1

X

Primary Species

Primary Species

ID (BLAST)

ID (SeqMatch)

X

X
13;8Fab.1:

A
13;1492
R
14;8F.ab
1

744

708

Corynebacterium

Corynebacterium

aurimucosum

aurimucosum

Streptococcus

Streptococcus

anginosus

anginosus

Streptococcus

Streptococcus

anginosus

anginosus

B
14;1492
R
15;8F.ab
C

1
15;1492

Notes

668

679

Actinomyces neuii Actinomyces neuii

721

Actinomyces neuii Actinomyces neuii

MIXED
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R
16;8F.ab
1

623

Enterococcus

Enterococcus

faecalis

faecalis

Enterococcus

Enterococcus

faecalis

faecalis

Staphylococcus

Staphylococcus

aureus

aureus

Staphylococcus

Staphylococcus

aureus

aureus

Staphylococcus

Staphylococcus

aureus

aureus

Staphylococcus

Staphylococcus

aureus

aureus

Streptococcus

Streptococcus

oralis, pneumoniae

sanguinis

D
16;1492
R
17;8F.ab
1

670

729

E
17
;1492R
18;8F.ab
1

707

690

F
18;1492
R
19;8F.ab
1

767

695

G
19;1492
R
20;8F.ab
1

Streptococcus
725

oralis, sanguinis,
mitis, pneumoniae

X

X

R

716

mitis, oralis

X
Actinomyces

10;8F.ab1:

Actinomyces

urogenitalis,

POOR

urogenitalis

naeslundii,

H
20;1492

Streptococcus

howellii, oris
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Fusobacterium
Fusobacterium growth was observed on BRU and FSA. Small, white isolated colonies were
observed after 72 hours. Larger colonies of the same morphology were observed on the BRU
plate than the FSA plate.

Figure 4: F. nucleatum Growth on BRU (left) and FSA (right)
3.4 Next Steps: potential pitfalls and future directions
The high prevalence of lactobacillus in the vaginal microbiome eliminated it as a potential
biomarker for the final device. Lactobacillus was not isolated from any of the tested subject’s
vaginal samples, which may suggest a need for improving use of anaerobic culturing to be more
likely to obtain lactobacilli.
F. Nucleatum and F. Necrophorum were determined strong microbial biomarker candidates
based on their association with cervical cancer and our ability to cultivate these species in the
lab. The other identified subsystems use Fusobacterium spp. as the bacterial biomarker of
interest.
Microbial biomarkers for high risk HPV warrant investigation. This would allow the device to
not only have the capabilities of detecting early stage cervical cancer, but also the ability to pick
up on high risk HPV infections that are strongly linked to the development of cervical cancer
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(Shannon et al, 2017). Studies show the potential of using other species found in the vaginal
microbiota as an indicator of HPV infection. Sneathia spp. has been described as a possible
microbiological marker of high risk HPV strains associated with the development of cervical
cancer and warrants consideration as a secondary biomarker to increase test specificity in future
device iterations (Lee et al., 2013).
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CHAPTER 4: Assay Platform
4.1 Introduction
In developing the Assay platform, or self-contained design which would house the selective
growth media described in Chapter 5, two common microbiology techniques were considered:
the plate and the tube. In developing this self-contained design, the anaerobic growth
requirement of Fusobacterium was the most important condition to be met in order to achieve
bacterial growth. Therefore, the two designs were evaluated based on their ability to maintain
anaerobic conditions.
4.2 Methods
Plate vs. Tube
The anaerobic environment created using jars described in Section 3.3 was not effective at
culturing lactobacillus and would not be portable. Therefore, other options were explored to
culture fusobacterium. The attempted anaerobic environment was created using Ziploc bags, a
gas pack, and anaerobic indicators. The gas pack would effectively remove oxygen from the
environment once the bag was opened or if oxygen leaked into the system. The anaerobic
indicators were used to determine if anaerobic conditions were maintained. Plates were streaked
with inoculated fusobacterium cultures and immediately placed into the anaerobic environment,
keeping air exposure to a minimum.
Swab Selection
To determine the swab type that resulted in the least oxygen exposure a series of five different
swabs without bacterial samples were tested in parallel experiments. In order to conduct the
experiment, anaerobic transport media tubes were used, which include a chemical resazurin,
which reacts with oxygen creating a color change. Each swab was submerged into the media tube
and dipped then removed from the media tube. The swabs tested included: the Cervex brush, the
cervical spatula, the cotton swab, the polyester swab, and the bristle brush. During testing each
tube was exposed to oxygen for no more than 15 seconds, the test was performed at room
temperature, and the tubes were checked after 24 and 48 hours.

32
Swab Mechanism
After the swab was selected the same test was repeated with this swab to further verify which
swabbing mechanism would result in the least amount of oxygen entering the system. The swab
was first submerged into the anaerobic transport media tube containing resazurin. In parallel, the
same swab was dipped and then removed from the media tube. The results of both trials were
compared.
4.3 Results
Plate vs. Tube
After attempting to create an anaerobic environment with Ziploc bags, the enclosure remained
anaerobic for the first 24 hours, but no bacterial growth was observed. Furthermore, by 72 hours
the anaerobic indicators changed color from pink to purple showing that the environment within
the Ziploc bags was no longer anaerobic, as shown in Figure 5. No growth was observed. It was
concluded that by the 72 hour mark the gas packs were no longer actively removing oxygen and
that anaerobic conditions were no longer maintained. Overall, anaerobic conditions necessary to
grow fusobacterium were not achieved.
Sandwich Bag + Quart Bag

Freezer Bag + Sandwich Bag

Double Freezer Bag

Figure 5: Anaerobic Systems Experiment after 72 hours
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Following the unsuccessful results creating an anaerobic environment to culture Fusobacterium,
attempts to culture the bacteria in the anaerobic hood began. Successful growth on plates was
then achieved as shown in Figure 3. However, it was concluded that it would be difficult to
create an entirely anaerobic environment using the plates, as oxygen exposure occurred across
the entire surface area of the plate, penetrating into the media. Therefore the tube design was
pursued per results which are discussed below.
Swabbing Mechanism
Table 4: Results of Swab Submersion Experiments
t=0
Cervex Brush

Cotton Swab

48 hours

72 hours
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Bristle Brush

Polyester Swab

Cervical Spatula

Table 4 above summarizes the results of the swab selection experiment. As indicated by the color
change, submerging the swab in the tube was the best method to maintain anaerobic conditions.
In conducting this experiment, the sizes of the cervex brush and cervical spatula were too big to
be inserted into the tube, and needed to be cut to fit, making their size an issue. The cotton swab
was also eliminated due to the toxic nature of the wooden handle which could prevent bacterial
growth. Between the polyester swab and bristle brush, research supported that the bristle brush
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collects a better sample than the polyester swab, so the bristle brush was selected. Table 12
below summarizes this selection.
Table 5: Final Swab Selection
Size

Toxicity

Collection

Cervex Brush

✓

✓

Cervical Spatula

✓

✓

Cotton Swab

✓

Polyester Swab

✓

✓

Bristle Brush

✓

✓

✓

✓

Table 13 shows the results of verifying the submersion swabbing mechanism as the best method
to maintain anaerobic conditions. As shown by the images below, leaving the bristle brush
submerged in the media resulted in the least oxygen exposure, indicated by the pink color change
isolated to the top of the tube.
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Control

Removed

Submerged

Figure 6: Sampling Mechanism Oxygen Exposure
These experiments informed the final design prototype. The design was decided to be a tube with
semi-solid media to maintain anaerobic conditions and keep the swab submerged to create a
self-contained test.
4.4 Next Steps: Potential Pitfalls and Future Directions
After deciding to move forward with the tube design, bacterial growth had yet to be observed.
Given the results from the anaerobic transport media, it was reasonably concluded that
conditions necessary for growth could be achieved as the bottom 70% of the tube remained
anaerobic.
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CHAPTER 5: Growth Media
5.1 Introduction
As noted in the introduction, the test for fusobacterium growth requires a selective media and an
anaerobic environment. The media developed fulfills these criteria through the methods listed
below.
5.2 Methods
Lab procedures focused on growing fusobacterium on both selective and non-selective solid
media plates incubated at 37°C. Both BRU and FSA contain blood and therefore appear dark red.
While this coloring actually increases the ease of growth observation on solid media plates, it
makes growth observation very difficult in media tubes. Therefore, a novel media, CERVIS 1.0
was developed to include the selectivity of FSA without incorporating blood. FSA contains three
antibiotics that select for fusobacterium: vancomycin, neomycin, and josamycin (Morgenstein,
Citron, & Finegold, 1981). Thus, CERVIS 1.0 contained all three of these antibiotics to maintain
the selectivity. To provide a nutrient rich media base, porcine Brain Heart Infusion (BHI) broth
was also added to the media. Porcine was selected over bovine or other options for ease of future
use. Some countries have laws against the transport of bovine material across borders for disease
prevention and protection, so porcine material is a safer choice. BHI was selected primarily
because it is transparent and prior research suggests that fusobacterium can grow optimally on
this media (Han, 2006). The complete list of ingredients in the media is listed in Appendix
Figure A.
In order to test the CERVIS 1.0, pure fusobacteria cultures of F. nucleatum and F. necrophorum
were plated and incubated at 37°C until colony formation was observed. Approximately two
colonies of each strain were taken from the plated cultures using a bristle brush, which was then
used to inoculate the media. The inoculated sample tubes were then incubated at 37°C outside of
the anaerobic chamber and growth was monitored over a period of 72 hours.
5.3 Results
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The non-selective media, Blood Brucella Agar (BRU) successfully grew Fusobacterium cultures
in the anaerobic chamber. The selective media, Fusobacterium Selective Agar (FSA), developed
by Anaerobe Systems was also successful in growing Fusobacterium colonies, but the observed
colonies were much smaller.
The first iteration of the CERVIS media, CERVIS 1.0, was a major milestone for the project’s
success. The media supported the growth of pure fusobacteria cultures of F. nucleatum and F.
necrophorum in tubes incubated at 37°C both inside and outside the anaerobic hood. This
proved that an obligate anaerobe could be grown in CERVIS media outside of a contained
anaerobic chamber and showed that the media successfully maintained anaerobic conditions.
Additionally, this proved that the media contained enough nutrients to support growth. However,
bacterial growth was difficult to distinguish from other artifacts or air bubbles within the media,
as shown in Figure 7.

Figure 7: Fusobacteria Growth in CERVIS 1.0 Media
The results of the tests using CERVIS 1.0 were difficult to interpret. Additionally, there was no
confirmation that the organisms growing in the tube really were Fusobacterium spp. In order to
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make a more accurate test where growth was easy to visualize, a secondary differential test for
the presence of fusobacteria was deemed necessary.
CERVIS 2.0 was developed to address the limitations of CERVIS 1.0. To identify growth more
easily and with better accuracy, components of a secondary test were implemented in the media.
The secondary test, modeled after Triple Sugar Iron (TSI) tubes, confirms that any growth seen
is actually fusobacterium. If enough cysteine is present in the media, fusobacterium can produce
dihydrogen sulfide (H 2 S) (Basic et al., 2015). This byproduct can then react with ammonium
iron (iii) sulfate hexahydrate, which acts as an H 2 S indicator and turns black when H 2 S is
present. Thus, the presence of fusobacterium, the media will turn a dark black color, in Figure 8
below, that is significantly different from the control golden color of the media in the absence of
fusobacterium. L-cysteine also acts as an oxygen reducing agent, eliminating the need for DTT
in CERVIS 2.0. resazurin was removed because the anaerobic conditions of the media were
already tested and proved and adding this color change was thought to interfere with the color
change from the secondary test. Additionally, magnesium sulfate heptahydrate was added to help
solidify the Gelrite to maintain the semisolid consistency (Basic et al., 2017).
The same experiments outlined in the CERVIS 1.0 media above were performed with CERVIS
2.0 media to measure and compare its functionality. The results shown in Figure 8 display the
growth of F. nucleatum (middle) and F. necrophorum (right) in CERVIS 2.0 media compared
against the control, with no bacterial sample introduced, seen on the left.
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Figure 8: Fusobacterium Growth in CERVIS 2.0 Media
As depicted, the media changed from a transparent, golden color, seen in the control sample, to a
murky black in both strains. This color change shows the product of the secondary test, which
confirms the presence of fusobacterium growth in the tube. Again, this test was performed
outside of the anaerobic chamber, confirming that the media maintained anaerobic conditions
sufficient for fusobacterium growth. To confirm that no other bacteria from a vaginal swab
would cause this color change, five members of the team performed vaginal swabs and inserted
them into CERVIS 2.0 media, following the procedures outlined in Section 3.2. The results of
this experiment are shown in Figure 9.
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Figure 9: Vaginal Swabs in CERVIS 2.0 Media
While each tube with a vaginal swab looks slightly cloudier than the control tube, there is no
color change, proving that no other presumably relevant bacteria would cause the color change
indicating the results of the test.
5.4 Next Steps: Potential Pitfalls and Future Directions
CERVIS 2.0 was successful in growing fusobacterium selectively, but the sensitivity of the
media is not yet known. Experimental plans to begin estimating the sensitivity of the media are
outlined in Section 6.2.1. Additionally, the color change in the presence of fusobacteria was only
observed at 37°C. At room temperature, some growth was observed but the media remained a
golden color. This indicated the need for some form of incubation, which must be considered for
the final device design and implementation.
It is not yet understood what other microbial species in the vaginal microbiome produce
hydrogen sulfate as a byproduct and will in turn, invoke the reaction in the presence of
L-cysteine to blacken the CERVIS media in the vial. Further testing is necessary to better

42
understand the validity of CERVIS as a viable screening method for early stage cervical cancer
and what the risk of false positives is due to other bacteria that can grow in CERVIS media and
invoke the reaction. To test this, samples from human cervical cancer patients must be collected
and tested.

43
CHAPTER 6: Conclusion & Future Directions
6.1 Prototype
Over the course of this project, a biomarker that has the potential to indicate the presence of
cervical cancer has been identified using emerging research on the vaginal microbiome, and a
novel screening test capable of selectively detecting for this species of bacteria from a patient
sample was designed. The scope of the project focused on the development of this prototype
through the creation of a selective media that incorporated the antibiotics from FSA media and
maintained anaerobic conditions through the use of a semi-solid media with oxygen scavengers.
The physical form of the assay incorporated a patient sample through the use of a vaginal swab
taken with a bristle brush. This sample applicator was selected from a group of five applicators
tested on the criteria of size, toxicity, and sample collection. The screening method is minimally
invasive as it only requires a single self-administered vaginal swab. The test is self contained as
the swab is inserted directly into the media and sealed with a cap. These characteristics of the
screening method help to minimize the need for clinically trained personnel to be present to
conduct the test or analyze the result; hopefully, alleviating the need for women to seek out
traditional clinical settings in order to gain access to preventative care. The final iteration of the
proposed design of the screening test currently costs less than $5 to manufacture, with the
hungate tube and cap being the most costly items. Reference Figure A in the Appendix for a
complete cost analysis.

Figure 10: CERVIS Prototype
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6.2 Sensitivity
To better understand the correlation of the bacterial samples from our initial tests compared to
the vaginal microbiome of a diseased patient, calculated estimations were made to investigate the
sensitivity of the CERVIS 2.0 prototype. It is known that 17% of the vaginal microbiome is
composed of fusobacterium in the case of Cervical Cancer (Audirac-Chalifour et al., 2016).
Bartlett et al., reports an average of 109 anaerobic bacteria in the average vaginal microbiome
(Bartlett, 1977).
Quantification of Fusobacterium in the Vaginal Microbiome of a Cervical Cancer Patient:
17% of 109 = 170, 000, 000
Mitra et al., notes the average bacterial load using a cytology (bristle) brush is 6.41. This value is
reported on a log base 10 scale. Therefore, assuming that the bacteria taken up by one sample
using the CERVIS 2.0 sampling device, 2570395 bacteria are collected by one swab.
Quantification of Fusobacterium in one swab from a Cervical Cancer Patient:
17% of 2,570,395 = 436,967
It is noted that these calculations are rough estimates, as the vaginal microbiome is highly
variable between individuals due to factors including sexual activity, menarche, menses, age,
pregnancy, infection, and birth control (Huang et al., 2014).
Next, the estimated number of fusobacterium in the diseased vaginal microbiome was compared
to the colonies taken up by the swab during experimentation. It is estimated that one colony
contains an average of 107 bacteria. For each plate of fusobacterium (F. necrophorum and F.
nucleatum) 2 colonies were collected using the cytology (bristle) brush. Under this assumption
20,000,000 bacteria of pure fusobacterium spp. respectively were delivered into each tube.
In conclusion, 436,967 bacteria (estimated patient sample) < 20,000,000 bacteria (estimated
experimental sample). Thus, these calculations are insufficient in correlating the vaginal
microbiome to colonies on a plate. Further sensitivity testing is required.
6.2.2 Preliminary Sensitivity Experiments
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To further estimate the sensitivity of the device, an experiment was designed under aerobic
conditions to estimate the threshold of bacteria needed to cause the color change in CERVIS 2.0
media. The experiment is outlined as follows:
Using BHI media, create a suspension of cells from a colony of F. necrophorum and F.
nucleatum. BHI broth from Anaerobe Systems is maintained anaerobically, which is why it was
chosen as the solvent over saline typical of a dilution series. These cultures were used to roughly
estimate cell density.
Serial dilutions were prepared using the cultures. To prepare the first dilution, add 1 mL of
culture to 99 mL BHI ( 10−2 dilution). Next, 1 mL of the 10−2 dilution should be added to
another 99 mL BHI to generate a 10−4 dilution. At this point, three further dilutions should be
prepared ( 10−5 to 10−7 ) adding new samples of f. Nucleatum and f. necrophorum to 4.5 ml BHI.
After completing the dilution series, a bristle brush should be used to take a sample from each
dilution. The brushes should be inserted directly into the CERVIS 2.0 media and the tubes
immediately resealed to maintain anaerobicity.
This experiment was not conducted due to unforeseen laboratory challenges. At the time of
scheduled experimentation, both control strains of fusobacterium previously plated on FSA were
dried, and well-defined colonies were not collectable by bristle brush. Thus, the starter culture
could not be made. Moving forward, sensitivity testing is necessary to validate the integrity of
the CERVIS 2.0 device.
6.3 Device Implementation
Human Subjects Research
There currently lacks adequate data to confirm that the bacteria introduced by a colony from a
pure culture represents the vaginal microbiome of a disease state. In order to clinically scale up
the device, a partnership with a research hospital is required to confirm device sensitivity and
specificity. Following the required protocols for human subjects testing, CERVIS 2.0 will be
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tested with patient samples from representative populations of the following categories: HPV
negative, HPV positive, intraepithelial lesions, and cervical cancer.
Clinical Trial in the United States
The results from the human subjects research testing will inform a clinical trial conducted within
the United States. To properly conduct a clinical trial, the IRB protocol and FDA 510-k filing
will be completed. The prototype will be classified as an in vitro diagnostic Medical Device for
self-testing, because it is intended by the manufacturer for use by lay persons and its
noninvasive nature. Additionally, since other medically established means of diagnosis of
cervical cancer exist, we will not need to file for an Investigational Device Exemption (IDE).
Sustainable Partnership with Aga Khan University
The clinical trial will be repeated in Kenya to guarantee the results are replicable within the
target population. Variations in the microbiome are dependent partially on the individual’s
environment, and this trial will ensure that the microbiome is consistent enough that
fusobacterium is an appropriate biomarker in this context.
Pilot Test within Target Community
Upon test validation, the device will be pilot tested in a community near Nairobi, Kenya in a
manner that is culturally appropriate. This may be completed by using the device initially in a
community setting, screening a number of women at a location they regularly frequent, similar to
a blood drive. Results from this test will inform how the device is deployed on a larger scale.
6.3.1 Supplemental to Current Screening Tests
Per current research, the Fusobacterium strains of interest are only present in the vaginal
microbiome of individuals with precancer and cancer. Although our device will never replace the
current diagnostic standard, our device is a less-invasive and lower-costing alternative that is
indicative of serious disease. For this reason, it is necessary to have a standard for referring
women who test positive to seek further screening and subsequent treatment. The methods for
further screening are outlined in Section 1.2, and the educational component included in the
CERVIS implementation strategy will contain relevant information about these methods and
available treatment options. Additionally, the targeted areas for pilot testing must have the means
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to access such subsequent methods. As device deployment is scaled up, methods of transporting
women from rural areas to more developed areas with a greater capacity for medical care must
be explored.
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CHAPTER 7: Engineering Standards
7.1 Manufacturability
Anaerobe Systems is the producer of the world’s only true pre-reduced anaerobically sterilized
(PRAS) culture media poured and packaged under anaerobic conditions (Anaerobic Chambers &
Culture Media Manufacturer, 2018). This company is currently the independent manufacturer of
CERVIS media. According to Anaerobe Systems product quality and development manager, it
takes between 4 – 6 different people to produce one liter of media, all with varying hourly pay
rates. The manufacturing procedure is outlined in the following paragraphs.
The Anaerobe Systems production manager first schedules the manufacturing and determines
who will make the media. He/She also orders all necessary components and ensures the correct
equipment is being used. Next, the mixing technician makes the media and starts the sterilization
process. Once the media is sterilized, another technician adds any heat labile components like the
antibiotics. Only a few people at Anaerobe Systems are authorized to do this since it takes a
skilled person to perform this procedure correctly without contaminating or harming the media.
Next, a different production technician hand pours the media in pre-sterilized tubes. They need to
be pre-sterilized beforehand since heat-labile components are added after the primary media is
sterilized. They cannot be sterilized in the tubes since that will destroy the antibiotics. This
increases the cost since a person needs to hand pour the media instead of just placing it on the
automatic tube pouring machine. That machine can only be used for media that can be sterilized
in the tube. The machine also pours tubes faster than a technician can. All the media is made
within larger anaerobic chambers in production, which have their own electrical expenses and
nitrogen gas consumption.
Once the tubes are poured, they need to be labeled and packaged in foil filled with nitrogen gas
and sealed. Some cost considerations include electricity, including the AC unit to maintain the
appropriate room conditions and the lights so employees can see. Additionally, autoclaves and a
boiler are used to make the steam for sterilization.
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Once the media goes to quality control for approval, a quality control technician conducts
sterility and performance tests on the media. This requires specialized skills and equipment
including an anaerobic chamber, incubators, and other general laboratory equipment like loops
and saline blanks. All necessary organisms are preemptively cultured on a general media like
Brucella blood agar (BRU). This machinery requires electricity to operate and the anaerobic
chamber requires expensive tri-mix gas. Once all the testing is completed, the quality control
manager approves and passes all media.
7.2 Ethics
The primary ethics question that arose from this project was: Is it ethical for a team from the
developed world with little first-hand knowledge of the cultural practices in the target location to
develop an alternative screening method and, if so, on what basis?
Developing and implementing a low-cost, minimally-invasive screening method that is
culturally relevant will benefit the common good and improve social justice because it will limit
the the need for more invasive procedures, increase the chances for successful treatment, and will
reduce incidence and mortality rates for women living in low- and middle-income countries.
There are a variety of stakeholders that warrant consideration when addressing this question. The
most important are the women living in Kenya who because of CERVIS will have a lesser
chance at contracting late stage cervical cancer compared to women in other similar sub-Saharan
countries. Additionally, community health workers, doctors, and volunteers involved in the care,
delivery, and education concerning our device have a stake in our project. Our team from Santa
Clara University, including students from the departments of bioengineering and public health
science, and our advisors from biology, bioengineering, and public health science all have a
stake because the researchers care about designing the device to work as intended and cause the
most benefit and least amount of harm to our target community.
On a greater scale, the members of the cervical cancer research community including researchers
and doctors from around the world have a stake because our device has the potential to reduce
the burden of disease significantly, especially for individuals in previously unreachable contexts.
Since the bacteria our device detects is indicative of other disease states in other microbiomes,
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this device has the potential to screen for other diseases beyond cervical cancer. This extends the
stakeholders beyond the cervical cancer community to dentists and other oncologists and
researchers. The employees at Anaerobe Systems, a corporate partner helping manufacture
CERVIS, hold a stake in terms of the viability of the product because they are interested in
expanding their market (primarily microbiology researchers working with anaerobic bacteria) to
helping people in the developing world. Society is always a stakeholder.
7.3 Other Emerging Work
Intellectual Ventures
A research team led by investigators from the National Institutes of Health (NIH) and Global
Good has developed a computer algorithm that can analyze digital images of a woman’s cervix
and accurately identify precancerous changes that require medical attention. This artificial
intelligence (AI) approach, called automated visual evaluation, has the potential to revolutionize
cervical cancer screening, particularly in low-resource settings. This new technology could
dramatically improve the screening capabilities of clinics in low-resource settings, as it requires
minimal training, which makes it ideal for contexts with limited resources. However, many
cultural barriers exist that prevent women from seeking out preventative care, and many women
only go to the clinic if they are experiencing symptoms or are pregnant. Therefore, one limitation
of this innovation is that it requires a clinical setting (AI approach outperformed human experts
in identifying cervical precancer, 2019).
Unitaid Projects
From May 2018 to September 2018, Unitaid collected submissions for projects seeking to help
eliminate the incidence of cervical cancer in low and middle income countries. Unitaid is aware
of the need for expanded access to screening in order to reduce the incidents of cervical cancer
deaths in these settings. Currently, Unitaid is developing two grants related to cervical cancer
screening and treatment, and at this time both have not been published. The projects are moving
into the final development stages and further information should be available in coming weeks
(Preventing Deaths from Cervical Cancer, 2018).
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7.4 Engineering Standards & Realistic Constraints
Economics, manufacturability, cultural impact, and health and safety are the engineering
standards affecting device design.
Economics
Pilot testing is intended to take place in Nairobi, Kenya and for this reason, the economic
landscape of Kenya must be evaluated. The low cost of CERVIS is aimed to address this
challenge, enabling women of all socioeconomic backgrounds the ability to be screened for
cervical cancer (See Appendix).
Manufacturability
The device is currently manufactured by Anaerobe Systems in Morgan Hill, CA. For long term
scale-up and sustainability, manufacturing options in Kenya warrant consideration.
Cultural Impact
Religion plays an important role in the life of most Kenyans, and the concept of virginity is
highly valued by both Christians and Muslims, the two most predominant faiths practiced in
Kenya (Spronk, 2005). In earlier iterations of our device, team CERVIS explored tampons and
menstrual cups as a means to collect blood samples from women that could be used to screen for
cervical cancer. However, after talking to several nurses working in sub-Saharan Africa, it
became clear that these items are not typically used due to a stigma that a “broken” hymen
equates to a loss in virginity. Despite having no identifiable role in the woman’s body, the hymen
retains significant religious and moral value in Kenyan society (Odongo, 2015). The uptake of
earlier detection methods was limited by the Kenyan belief that hymenal integrity signifies
virginity, and women would not use earlier collection methods because of the fear of tearing the
hymen.
Our current prototype requires a woman to self-swab her vagina using a small, soft bristle brush.
Although this is less-invasive than a tampon, a woman using our device may have similar fears
about virginity after inserting the swab. To address these fears, an educational component
designed by nurses and educators working in the field to help women understand their anatomy,
the benefits of screening, and how to use our device effectively would be necessary. A hymen
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can be “broken” through sex, by using a tampon or a menstrual cup, doing sports, or visiting a
gynecologist, and misunderstanding this information poses challenges in implementing cervical
cancer screening interventions (Sayer, 2018).
Health and Safety
Health and safety is the most important factor under consideration. To ensure this goal is
maintained and monitored, an educational program should be co-developed by educators,
volunteers, and healthcare workers on the ground that helps to explain a woman’s anatomy and
the importance of screening for cervical cancer in addition to creating an alternative low-cost
screening method and deploying it in Kenya. A plan to increase access to subsequent screening
and treatment options for women who test positive after using CERVIS must also be put into
place.
Additionally, once a vaginal swab is administered and introduced to the media, CERVIS 2.0
becomes a biohazard that needs to be disposed of properly to maintain the health and safety of
the community. Establishing clear, well-defined policies to ensure proper disposal must be put in
place prior to device implementation.
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APPENDICES
Table A: Summary of Goals, Objectives, and Expected Results
Goals
Create an alternative

Objectives
Develop a working prototype

screening method for cervical

Expected Results
A final sketch of a proposed
device

cancer
Device must not require a

Develop a test that is easy to

The final device can be

clinical setting

use without laboratory

self-administered as an

equipment or medical

at-home test

expertise
Device must be

Develop a handheld device

Device will resemble a

self-contained

that does not contain any

pregnancy test

loose components
Device must be low-cost

Create a device for less than

Cost will depend on final

existing methods

biomarker selection

Device must produce a binary

Create an output that is easily

Device produces a binary

output

interpreted in the field (+/-)

output when introduced to a
biomarker

Device must be deployable in

Create sustainable

Partnerships formed

low- and middle-income

partnerships with healthcare

throughout the year will be

countries

workers in the field

professional and provide
information through
interviews to inform the
cultural relevance of the
project
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Table B: Funding Received
Funding Received

School of Engineering

$2000

Xilinx Grant

$500

Total Received

$2500

Table C: CERVIS Expenditures
Product

Company/

Product

Description

Provider

Number

FSA media

Anaerobic

Unit Cost

Total Cost

Date
Ordered

353136

9.18

45.9 1/11/19

Biomerieux

46968

73.93

128.01 1/17/19

Biomerieux

46971

1.28

42.73 1/21/19

25586

133.26

133.26 1/29/19

3381118

20.42

20.42 1/31/19

353136

9.18

45.9 2/4/19

Systems
Anaerobic
pouches
Anaerobic
Indicator
Fusobacterium ATCC
nucleatum
subsp.
Anaerobic

Anaerobic

Transport

Systems

Medium
FSA media

Anaerobic
Systems
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Fusobacterium ATCC

25586

133.26

133.26 2/12/19

252199

0.59

58.91 2/12/19

88404127

640.24

nucleatum
subsp.
Puritan

Marketplace

Cytology

Direct

Bristle
Brushes
Anaerobic

Praxair

640.24 4/8/19

Chamber Gas
Total Spent

1,230.27

Table D: 2018-2020 Academic Timeline for CERVIS
Fall Quarter
Week 1

Winter Quarter

Spring Quarter

First meeting after

Working in Dr. Stephens

CERVIS1.0 results

summer recess with

microbiology lab is

collected and analyzed

Primary Advisor Dr.

confirmed

Prashanth Asuri

Fusobacterium is selected

Partnership formed

as the bacterial biomarker

between BIOE students

of interest

and EWH students

Second collaborative
effort with Anaerobe
Systems to design
CERVIS2.0

EWH & BIOE students
draft preliminary
experiments for winter
quarter lab work

Week 2

First meeting with all
team members-

Accepted to present at

CERVIS 2.0Media
Tested with Pure Strains
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brainstorming session on
prospective analytes and
biomarkers

Unite for Sight Conference
Environmental Health and
Safety form approved for
Stephens lab
Initial materials order
placed
Registration confirmed for

of Fusobacteria spp. and
samples from female
group members
Short presentation
delivered to advisory
board members
(Bioinnovation &
Design)

Senior Design Conference
presentation
Week 3

Second Frugal Innovation

Final Frugal Innovation

workshop with Gregory

workshop with Gregory

Theyel

Theyel
Unite for Sight Global
Health & Innovation
Conference

Week 4

Week 5

Crashing brainstorming

Anaerobicity experiments

GHTC Paper submitted

session- bacteria

run in lab; attempt to grow

for review

biomarker idea comes to

fusobacterium in a

fruition

micro-aerobic environment

Dr. Craig Stephens joins

CERVIS team runs the

the team- preliminary

Kaiser Permanente San

budget/list of material

Francisco half marathon

submitted to School of
Engineering

Colonies grown under
different aerobic conditions
analyzed using 16s

Sensitivity Testing

61
ribosomal RNA sequencing
Meeting with Dr. Ruscetti
alters project trajectoryrefocused on device design
Week 6

First Frugal Innovation

Conversation with Lata

Senior Design

workshop with Gregory

Mukundan from CCSA for

Conference

Theyel

a discussion on the
therapeutic potential of the
human microbiome
Dr. Ruscetti guided a
training session to work in
the anaerobic hood
Control culture of F.
nucleatum was plated and
streaked for isolation on
FSA under anaerobic
conditions
Meeting with Mike Cox
and Hiram Lonzo at
Anaerobe Systems inspires
device prototype

Week 7

Week 8

Preliminary experiments

IEEE Conference

Finalize Thesis Rough

run in attempt to

Presentation at San Jose

Draft

cultivate lactobacillus

State University
Coordinate Next Steps
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for Project Continuation
Week 9

Week
10

EWH students begin

Submit Thesis to

working on abstract for

Bioengineering Adviser

GHTC

for Revisions

Group meeting with all

Experimental lab work in

advisors, EWH, and

the anaerobic hood using

BIOE students; recess

CERVIS 1.0 Media

Final Thesis Submission

until post winter break

Table E: Information about Vaginal Microbiota
Species

L.

Gram

Fermentatio

(-/+)

n products

+

H2O2 (can

crispatus

Morphology

Rods

O2

Other important

tolerance

characteristics

Obligate

-Approx 60%

Source:

https://ww

be used as

anaerobe- healthy vaginal

w.ncbi.nl

antimicrobia

aerotolera biome

m.nih.gov/

l agent)

nt

-produce

pmc/articl

Lactic acid

antibiotic

es/PMC49

(lower

products that

85617/

environment

target E.coli and

al pH-

Candida

another
antimicrobia
l attack)
G.

gram

G. vaginalis

Coccobacilli

Facultativ -Is the main

https://ww

vaginalis

variabl

ferments a

(Short rods)

e

w.ncbi.nl

e

wide variety Nonmotile

cause of

anaerobes Bacterial

m.nih.gov/

63
of

Vaginosis

pubmed/6

carbohydrat

-it has been

389437

es,

found in 15% to

producing

69% of women

https://ww

acetic acid

without signs or

w.science

as an end

symptoms of

direct.com

product. G.

vaginal infection /topics/me

vaginalis

-G. vaginalis

dicine-and

does not

can be sexually

-dentistry/

reduce

transmitted

gardnerell

nitrate or

-Its role in

a-vaginali

hydrolyze

pathogenesis

s

urea.

may be through
altering the

Negative

microbial

catalase test

environment due
to RBC lysis
releasing iron
metabolites or
through altering
the host
response

L. Iners

+

Catalase

Rods

Facultativ

Variab

negative

e

https://ae

le

lactic acid

anaerobe

m.asm.org

bacteria

/content/a

group (i.e.

em/early/2

they convert

016/09/26/
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sugars to

AEM.023

lactic acid).

85-16.full.
pdf
https://ww
w.cell.co
m/trends/
microbiol
ogy/pdf/S
0966-842
X(16)301
81-0.pdf

L. Gasseri

+

Catalase

Rods

anaerobic

negative

More common

https://mic

in the colon- not

robewiki.k

super worried

enyon.edu

about this one

/index.php
/Lactobaci
llus_gasse
ri

L.
Jensenii

+

Catalase
negative

Rods

anaerobic

It is one of the

https://mic

predominant

robewiki.k

species (along

enyon.edu

with

/index.php

Lactobacillus

/Lactobaci

crispatus) found

llus_jense

in the female

nii

lower genital
tract
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S.

+

Catalase

Agalactia

negative

e

Lactic acid

Spherical

Microaer

- Causes

https://ww

ophilic

meningitis in

w.science

neonates and

direct.com

elderly

/sdfe/pdf/d

- Occasionally

ownload/e

colonizes female id/3-s2.0reproductive

B9781437

tract

72702900

- Increase risk

1215/first-

for premature

page-pdf

rupture of
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membranes and

w.sigmaal

transmission of
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infection to

technical-

child

documents
/articles/a
nalytix/str
eptococcioverview.
html

L.

undergoes
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Acidophil
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n only

ontent/45/
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4/8/19 at 09:44:39.04

Page: 1

Anaerobe Sys tems
Bill of Materials Report
As of Apr 8, 2019
Filter Criteria includes: 1) Item ID's from WP-MED-723 to WP-MED-723. Report order is by Item ID. Report is printed in Detail format with with shortened
descriptions.
Item ID

Item Descript ion

W P-M ED-723
. RM-0525
. RM-3480
. RM-0930
. RM-1580
. RM-33 50
. RM-2020
. RM-1320
. RM-1720
. RM-0152
WP-M ED-723 Total

CERV IS MEDIUM
BRAIN HEART INFUSION- PO RCINE
YEAS T EXTRACT TECH GRA DE
CYSTE INE-SIGMA
JOSAMYC IN
VANCOMYC IN
NEOMYC IN TRISU LFAT E
GELLAN GUM
MAGNESIUM SUL FATE HEPTAHY D
AMMON IUM IRON II SULFATE HEXA

Qty Needed

Qty on Ha nd

Est Cost

37 .00
5.00
1.00
0.00
0.0 1
0.16
4 .00
0.10
0.20

873 .00
1791 .76
2327 .77
0.21
31.55
43 .23
4248.00
1465.45
2.00

12.95
0.70
0.60
3.99
0.44
0.31
1.44
0.0 1
20.44
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4/8/19 at 09:46 :29.18

Page: 1

Anaerobe Systems
Bill of Materials Report
As of Apr 8, 2019
Filter Criteria includes: 1) Item ID's from WP-PACK-723 to WP-PACK-723. Report order is by Item ID. Report is printed in Detail format with with shortened
descriptions.
Ite m ID

Ite m Description

W P-PACK -723
. RM-2415
. W P-EA-723
W P-MED-723
... RM-0525
... RM-3480
... RM-0930
... RM-1580
.. RM-3350
... RM-2020
. .. RM-1320
... RM-1720
... RM-0152
.. RM-3079
LABOR
.. OV ERHEAD
. . W P- 1470
. RM- 1470
. RM-1480
. .. LB R-0020
. RM- 1598
WP-PACK- 723 Tota l

CERVIS MEDIUM
POUCH ES ANA EROBIC 6 x 7.25
CER VIS MEDIUM
CERVIS MEDIUM
BRA IN HEART INFUSION-PORC INE
Y EAST EXTRACT TECH GRA DE
CYST EINE-SIGMA
JOSA MYCIN
VANCOM YCIN
NEOMYC IN TRI SUL FATE
GELLAN GU M
MAGNESIU M SUL FATE HEPTAHY D
A MMONIU M IRON II SULFAT E HEXA
TE ST TUBES 16x100
An aerobe Lab Labo r Rate
FACTORY OV ERHEA D
HUNGA TE ASS EMBLED
HUNGAT E CAPS- BLACK
HUNGATE STOPPER S
CONTRACT CA P/STO PPE R ASS EM
LA BELS- AS TH ERMAL

Qty Needed

Qty on Hand

Est Cost

1.00
10.00
0 .07
2 .59
0 .35
0 .07
0 .00
0 .00
0 .01
0 .28
0 .01
0 .01
10.00
10.00
10.00
10.00
10.00
10.00
10.00
1.00

34664 .00

0.21

873 .00
1791 .76
2327 .77
0.21
31 .55
43.23
4248 .00
1465.45
2.00
42062 .00

0.91
0.05
0.04
0.28
0.03
0.02
0.10
0.00

54758 .00
18400 .00

86667 .00

1.70

0.50
1.40
0.06
5.30

4/8/19 at 09:49:06.76

Page: 1

Anaerobe Systems
Bill of Materials Report
As of Apr 8, 2019
Filter Criteria includes: 1) Item ID's from WP-EA-723 to WP-EA-723. Report order is by Item ID. Report is printed in Detail format with with shortened
descriptions.
Item ID

It em Desc riptio n

W P-EA-723
. W P-M ED-723
.. RM-0525
. . RM-3480
. . RM-0930
.. RM- 1580
.. RM-33 50
. . RM-2020
.. RM- 1320
.. RM- 1720
.. RM-0152
. RM-3079
. LA BOR
. OV ERHEA D
. W P- 1470
. . RM- 1470
.. RM- 1480
.. LBR -0020
WP -EA-723 Tota l

CERVIS MEDI UM
CERV IS MEDIUM
BRAIN HEART INFUSION-PORCIN E
Y EAST EXTRAC T TECH GRA DE
CYST EINE-SIGMA
JOSAM YCIN
VANCOM YCIN
NEOMYCIN TRISULFATE
GELL AN GU M
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Qty Needed

0 .01
0 .26
0 .04
0 .01
0 .00
0 .00
0 .00
0 .03
0 .00
0 .00
1.00
1.00
1.00
1.00
1.00
1.00
1.00

Qty on Hand

Est Cost

873.00
1791 .76
2327 .77
0.21
31 .55
43 .23
4248 .00
1465.45
2.00
42062 .00

0.09
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0.03
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0.01
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54758 .00
18400 .00

0.17

0.05
0.14
0.50

Figure A: Anaerobe Systems Bill of Materials

